Morgan Petronelli

The U.S. Food and Drug Administration has approved FMX103 (ZILXI, Menlo Therapeutics), a topical 1.5% minocycline foam for the treatment of inflammatory lesions of rosacea in adult patients.

A study from the University of Washington Medicine in Seattle pinpoints one of two lesions that can be attributed to UV light-caused skin cancer.

DermYoung and Eden MedSpa announce the launch of their “Together We Are Love, Together We Will Heal,” campaign which aims to provide NYC first responders with facials and take-home skincare kits for those experiencing skin damage and irritation due to PPE usage.

The U.S. FDA has approved dupilumab (Dupixent, Sanofi and Regeneron) for the treatment of atopic dermatitis in children 6-11 years, making it the first biologic approved for atopic dermatitis in this particular age group.

Dermavant announces the publication of their phase 2b clinical trial investigating tapinarof cream for the treatment of adult plaque psoriasis in The Journal of the American Academy of Dermatology (JAAD).

Bluestone Sunshields is helping fill the gaps of PPE available to those working on the frontlines of the COVID-19 pandemic by converting their UV ray-blocking visors into clear face shields.

In this week's edition we take a look at the world of injectables, the effects diabetes can have on the skin and how to correctly administer an at-home chemical peel. 

DMK Skin Care announces the donation of their new sanitizer spray for all licensed clinics. The product is optimized to sanitize clothing, surfaces and skin.

Mantra Mask announces the launch of two new sheet masks and eye gels containing CBD, adding to their portfolio of their all-natural skincare products.

In this week's edition, we feature stories on proper sunbrun treatment, breakouts after stopping birth control, how anxiety was affecting one writer's skin and why maintaining a good skincare routine is essential during the pandemic.

The U.S. FDA has granted an emergency use authorization to Everlywell Inc., to conduct and collect at-home testing for COVID-19.

Dr. Suneel Chilukuri of Refresh Dermatology located in Houston, Tx., sits down with Dermatology Times to discuss the aesthetic needs of millennial patients and what they've been requesting, such as treatment for 'tech neck' and much more.

Galderma announces positive results from their recent DREAM clinical study evaluating patient safety and satisfaction of abobotulinumtoxinA (Dysport) for glabellar lines when injected twice a year.

A recently published study in JAMA Dermatology showcases positive results for a face aging app’s effect on adolescent skin cancer protection behavior.

This week we highlight articles about teledermatology, sunscreen use for POC, seasonal allergeries' effect on skin, 'maskne' and many more.

The American Academy of Dermatology (AAD) announces the debut of their AAD VMX 2020, a virtual meeting being held June 12-14 in lieu of the annual AAD conference that was set to take place in March in Denver but cancelled due to COVID-19 concerns.

Amgen releases positive phase 3 results evaluating U.S. FDA-approved apremilast (Otezla) for the treatment of mild-to-moderate plaque psoriasis in adults.

A recent clinical review proves trifarotene 0.005% cream is an effective and safe treatment for acne vulgaris on the face and neck in patients 9 years and older. Currently, the drug is one of four topical retinoid acne treatments available on the market.

A new way to avoid contact with contaminated surfaces is now available through 5th Axis, a San Diego, Calif.-based machinery manufacturer. The company has created the StepHandle, a door handle that can be operated with a foot.

Galderma announces the U.S. Food and Drug Administration has approved hyaluronic acid lip filler, Restylane Kysse, in patients 21 years and older.

In this week's edition of The Mainstream Patient, we take a look at actinic keratosis, acne's connection to mental health, what working on the front lines of the pandemic can do to your skin, wearing sunscreen indoors and more. 

Ortho Dermatologics announces the U.S. FDA supplemental New Drug Application approval for efinaconazole 10% (JUBLIA) for the treatment of onychomycosis, a fungal toenail infection, in patients 6 years and older.

Gilead announces results from their phase 3 trial investigating different dosing durations for the investigational antiviral drug remdesivir.

REVIAN, Inc. releases positive data from their study investigating the REVIAN RED dual wavelength 620 nm and 660 nm light therapy device as a therapy for scalp pruritus and irritation.

In this week's edition of The Mainstream Patient, we share some stories aboout milia and blackhead treatment, what exercising with the wrong face mask can do to your skin, why you shouldn't resort to cutting off your skin tags during the pandemic and why you should avoid giving yourself a stick and poke tattoo. 

Menlo Therapeutics announces its wholly-owned subsidiary Foamix Pharmaceuticals Ltd.  is entering a licensing with Cutia Therapeutics for the company’s FDA-approved 4% topical minocycline foam (AMZEEQ, Foamix) for acne vulgaris in pediatric and adult patients.

In this week's edition, we share stories about the difference between psoriasis and eczema, starting a beauty company in the midst of a pandemic, skin rashes in COVID-19 patients, "skin fasting" and isolation-induced adult acne. 

Dermavant announces the enrollment completion for their two phase 3 clinical trials investigating the topical therapeutic aryl hydrocarbon receptor (TAMA) tapinarof as a treatment for adult plaque psoriasis, with results from the study still expected in the second half of 2020 despite the current pandemic.

A new symptom is popping up in COVID-19 patients. The virus can reportedly affect not only the lungs, but other internal organs as well as the senses – and now dermatologists are observing skin reactions in patients with the disease.